Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
Not Tagged | afm-24 | affimed | Not Tagged | 1 | ['afm24'] | 6/5/2022 2:01 | 1,530,000,000,000,000,000 | #asco22 | omar saavedra is delivering two presentations to explain the design and rationale behind the first clinical trials in humans with afm24, a bi-specific antibody capable of enhancing immune response. | Leading translational research to accelerate & advance personalized and targeted therapies against cancer.
@iCERCA centre | Company / Organization | Research / Science |
Not Tagged | Not Tagged | affimed | Not Tagged | 1 | ['affimed'] | 6/5/2022 8:21 | 1,530,000,000,000,000,000 | when you are little gets you chair #nkcells #asco22 $afmd #latinasinmedicine | Immunologist&Oncologist| LifeScience Entrepreneur Committed to Cancer Patients USLead @Affimed Alumni @mayoclinic @hopkinskimmel Philanthropist & ImpactInvestor | Individual | HCP |
not tagged | not tagged | affimed | not tagged | 1 | ['$afmd'] | 6/6/2022 16:36 | 1,530,000,000,000,000,000 | wtf is wrong with $afmd, they didn't even present at asco yet still get murdered. | Biosquidgames organizer ?????????????????? | Individual | Blogger / Random / Other |
Not Tagged | Not Tagged | affimed,oncternal therapeutics,curis | Not Tagged | 1 | ['$afmd', '$cris', '$onct'] | 6/4/2022 18:05 | 1,530,000,000,000,000,000 | why $cris stock jumped this week. $xbi $onct $pirs $afmd | Investor looking for big upside stocks. All opinions are my own, especially the bad ones. | Individual | Finance / Investment |
flex | not tagged | agendia | other | 1 | [] | 6/6/2022 8:15 | 1,530,000,000,000,000,000 | #cedarssinaicancer at #asco22. dr. m. william audeh is co-author on the poster whole transcriptome analysis of #tumors with discordant oncotype and #mammaprint results in the flex trial. | Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report. | Company / Organization | Hospital / Clinic |
FLEX | not tagged | Agendia | other | 1 | ['breast'] | 6/6/2022 3:06 | 1,530,000,000,000,000,000 | #agendia presents data from the #flex real world evidence trial in seven posters at #asco22 showcasing the power of its 30,000-patient #breastcancer genome project | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | not tagged | agendia | not tagged | 1 | [] | 6/6/2022 13:55 | 1,530,000,000,000,000,000 | #asco22 we want to see you! will donate $10 to for each poll submission. visit us at booth #19143 to cast your vote today! view all agendia's asco 2022 activities here: | We believe in delivering precision oncology to patients and physicians, empowering them with clear answers—and peace of mind—about their cancer treatment path. | Company / Organization | Healthcare |
not tagged | not tagged | agendia | Not Tagged | 1 | [] | 6/4/2022 10:24 | 1,530,000,000,000,000,000 | - agendia presents data at asco 2022 pointing to new signature imprint immunotherapy prediction and expansion of proprietary genomic tests utility to identify patients who will benefit most from specific treatments - ... | Press Releases from Around the Globe distributed to a Worldwide Audience via Web, Email & Social Media. | Company / Organization | Media / News |
not tagged | not tagged | agendia | Not Tagged | 1 | [] | 6/4/2022 11:49 | 1,530,000,000,000,000,000 | join at #asco22 as we review new clinical data showcasing the strengths of #mammaprint & #blueprint and raise donations for . find out more information here: | We believe in delivering precision oncology to patients and physicians, empowering them with clear answers—and peace of mind—about their cancer treatment path. | Company / Organization | Healthcare |
not tagged | not tagged | agendia | Not Tagged | 1 | [] | 6/4/2022 14:54 | 1,530,000,000,000,000,000 | agendia presents data at asco 2022 pointing to new signature imprint immunotherapy prediction and expansion of proprietary genomic tests' utility to identify patients who will benefit most from specific treatments - business wire | We deliver the latest Genomics news everyday | Company / Organization | Media / News |
not tagged | not tagged | agendia | Not Tagged | 1 | [] | 6/4/2022 14:54 | 1,530,000,000,000,000,000 | agendia presents data at asco 2022 pointing to new signature imprint immunotherapy prediction and expansion of proprietary genomic tests' utility to identify patients who will benefit most from specific treatments - business wire | Your source for the latest news on Genomics ; | Company / Organization | Media / News |
not tagged | not tagged | agendia | not tagged | 1 | [] | 6/6/2022 3:05 | 1,530,000,000,000,000,000 | #agendia presents data at #asco22 pointing to new signature imprint #immunotherapy prediction and expansion of proprietary #genomic tests utility to identify patients who will benefit most from specific treatments | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['sclc', 'ak112', 'nsclc'] | 6/6/2022 14:11 | 1,530,000,000,000,000,000 | #asco22 discussion of posters focused on overcoming immunotherapy resistance in nsclc led by dr. including #9019 on ak112 (pd-1/vegf bispecific) from dr. yuangyuan zhao. rr 40% and mpfs 6.5m in cohort 3 (post platinum chemo and io). | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
Not Tagged | ivonescimab | akesobio | thoracic | 1 | ['nsclc', 'ivonescimab', 'ak112', 'sclc', 'akeso'] | 6/5/2022 20:45 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) for advanced nsclc at asco 2022 #stocksmarket #pressrelease | Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases. | Bot / Aggregator | Finance / Investment |
Not Tagged | cadonilimab | akesobio | Not Tagged | 1 | ['cadonilimab', 'ak104', 'akeso'] | 6/5/2022 20:45 | 1,530,000,000,000,000,000 | akeso announces oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022 #stocksmarket #pressrelease | Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases. | Bot / Aggregator | Finance / Investment |
Not Tagged | ivonescimab | akesobio | thoracic | 1 | ['nsclc', 'ivonescimab', 'ak112', 'sclc', 'akeso'] | 6/5/2022 20:45 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) combined with chemotherapy in advanced nsclc at asco 2022 #stocksmarket #pressrelease | Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases. | Bot / Aggregator | Finance / Investment |
Not Tagged | ivonescimab | akesobio | thoracic | 1 | ['nsclc', 'ivonescimab', 'ak112', 'sclc', 'akeso'] | 6/5/2022 20:53 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) combined with chemotherapy in advanced nsclc a | null | Bot / Aggregator | Finance / Investment |
Not Tagged | cadonilimab | akesobio | Not Tagged | 1 | ['cadonilimab', 'ak104', 'akeso'] | 6/5/2022 20:53 | 1,530,000,000,000,000,000 | akeso announces oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for th | null | Bot / Aggregator | Finance / Investment |
Not Tagged | ivonescimab | akesobio | thoracic | 1 | ['nsclc', 'ivonescimab', 'ak112', 'sclc', 'akeso'] | 6/5/2022 20:53 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) for advanced nsclc at asco 2022 | null | Bot / Aggregator | Finance / Investment |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['sclc', 'ak112', 'ivonescimab', 'nsclc', 'akeso'] | 6/6/2022 2:52 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) combined with chemotherapy in advanced nsclc at asco 2022 #organic #health #food #cooking | Organic Holistic Sustainable Collective | Company / Organization | Advocacy / Charity |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['sclc', 'ak112', 'ivonescimab', 'nsclc', 'akeso'] | 6/6/2022 2:52 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) for advanced nsclc at asco 2022 #organic #health #food #cooking | Organic Holistic Sustainable Collective | Company / Organization | Advocacy / Charity |
not tagged | cadonilimab | akesobio | not tagged | 1 | ['ak104', 'cadonilimab', 'akeso'] | 6/6/2022 2:52 | 1,530,000,000,000,000,000 | akeso announces oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022 #organic #health #food #cooking | Organic Holistic Sustainable Collective | Company / Organization | Advocacy / Charity |
not tagged | cadonilimab | akesobio | not tagged | 1 | ['ak104', 'cadonilimab', 'akeso'] | 6/6/2022 3:12 | 1,530,000,000,000,000,000 | #akeso announces oral presentation featuring promising clinical data of #cadonilimab (#pd1 #ctla4 #bsabs #ak104) for the first-line treatment of r/m #cervicalcancer at #asco22 | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['sclc', 'ak112', 'ivonescimab', 'nsclc', 'akeso'] | 6/6/2022 3:12 | 1,530,000,000,000,000,000 | #akeso releases promising data of #ivonescimab (#pd1 #vegf #bsabs #ak112) for advanced #nsclc at #asco22 | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['sclc', 'ak112', 'ivonescimab', 'nsclc', 'akeso'] | 6/6/2022 15:39 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) combined with chemotherapy in advanced nsclc at asco 2022 | TrendRadars | Bot / Aggregator | Blogger / Random / Other |
not tagged | cadonilimab | akesobio | not tagged | 1 | ['ak104', 'cadonilimab', 'akeso'] | 6/6/2022 18:01 | 1,530,000,000,000,000,000 | akeso announces oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022 | TrendRadars | Bot / Aggregator | Blogger / Random / Other |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['ivonescimab', 'sclc', 'nsclc', 'ak112', 'akeso'] | 6/7/2022 1:27 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) for advanced nsclc at asco 2022. click the link to find more details. | We are dedicated to the research, development, manufacturing and commercialization of novel antibody drugs that are affordable to patients worldwide.
#9926.HK | Company / Organization | Pharma / Biotech |
not tagged | ivonescimab | akesobio | thoracic | 1 | ['ivonescimab', 'sclc', 'nsclc', 'ak112', 'akeso'] | 6/7/2022 1:21 | 1,530,000,000,000,000,000 | akeso releases promising data of ivonescimab (pd-1/vegf bsabs, ak112) combined with chemotherapy in advanced nsclc at asco 2022. click the below link to find more details. | We are dedicated to the research, development, manufacturing and commercialization of novel antibody drugs that are affordable to patients worldwide.
#9926.HK | Company / Organization | Pharma / Biotech |
not tagged | cadonilimab | akesobio | not tagged | 1 | ['ak104', 'cadonilimab', 'akeso'] | 6/7/2022 1:08 | 1,530,000,000,000,000,000 | akeso announced oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022. click the link to find more details: | We are dedicated to the research, development, manufacturing and commercialization of novel antibody drugs that are affordable to patients worldwide.
#9926.HK | Company / Organization | Pharma / Biotech |
not tagged | not tagged | alaunos therapeutics | not tagged | 1 | ['$tcrt'] | 6/6/2022 18:48 | 1,530,000,000,000,000,000 | $tcrt they were not so sure that they would even need il-2?--(arm b part) of course it's known that tcr-t trials can use other cytokines (il7, il15, & il2) in manuf.//expansion. maybe only needed just #1 patient to figure it out (*28 days discovery) > | Long term biotech investor/trader; healthcare field; tend to hold a few names long term; follow at your own risk {Not advice} Do your own due diligence! b4 buy. | Individual | Finance / Investment |
not tagged | not tagged | alaunos therapeutics | other | 1 | ['solid tumor', '$tcrt'] | 6/6/2022 22:34 | 1,530,000,000,000,000,000 | #asco22 $tcrt first-in-human phase 1/2 study of autologous t cells engineered using the sleeping beauty system transposon/transposase to express t-cell receptors (tcrs) reactive against cancer-specific mutations in patients with advanced solid tumors | No investment advice. Do your own DD Market is all about taking the shares from the weak holders& providing opportunities to those that have the stamina to hold | Bot / Aggregator | Finance / Investment |
Not Tagged | Not Tagged | alkermes | Not Tagged | 1 | ['alkermes'] | 6/3/2022 11:26 | 1,530,000,000,000,000,000 | which research focus area are you most interested to learn about during #asco22? | Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc | Company / Organization | Pharma / Biotech |
artistry-6 | nemvaleukin alfa,alks 4230 | alkermes | melanoma | 1 | ['melanoma', 'artistry-6', 'nemvaleukin'] | 6/6/2022 12:25 | 1,530,000,000,000,000,000 | #cedarssinaicancer at #asco22. artistry-6: nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous #melanoma with co-authors dr. omid hamid & dr. inderjit mehmi is being presented. | Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report. | Company / Organization | Hospital / Clinic |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 9:59 | 1,530,000,000,000,000,000 | awesomecapital: alkermes plants oncology flag at asco | null | Bot / Aggregator | Finance / Investment |
Not Tagged | nemvaleukin alfa | alkermes | Not Tagged | 1 | ['nemvaleukin'] | 6/4/2022 13:31 | 1,530,000,000,000,000,000 | nemvaleukin, interleukin-2 receptor agonist, il-2 still around! possible need for combination with ici.
phase 1 trial with good safety profile.
#asco22 | Hematology and Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, IO fan, trialist and skin cancer specialist to be! | Individual | HCP |
ARTISTRY | Not Tagged | alkermes | Not Tagged | 1 | ['alkermes'] | 6/5/2022 13:36 | 1,530,000,000,000,000,000 | we are excited to be at #asco22, where we are presenting data from our artistry clinical program and learning about the latest developments in #immunooncology. | Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc | Company / Organization | Pharma / Biotech |
artistry-6 | alks 4230 | alkermes | melanoma | 1 | ['melanoma', 'artistry-6', 'alkermes'] | 6/6/2022 7:58 | 1,530,000,000,000,000,000 | mucosal melanoma can be difficult to diagnose, and treatment options have historically been very limited for patients. our artistry-6 clinical trial presents an opportunity to evaluate a potential treatment option for this rare type of cancer. #asco22 | Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc | Company / Organization | Pharma / Biotech |
artistry-6 | alks 4230 | alkermes | melanoma | 1 | ['melanoma', 'artistry-6', 'alkermes'] | 6/6/2022 8:47 | 1,530,000,000,000,000,000 | mucosal melanoma can be difficult to diagnose, and treatment options have historically been very limited for patients. our artistry-6 clinical trial presents an opportunity to evaluate a potential treatment option for this rare type of cancer. #asco22 | Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc | Company / Organization | Pharma / Biotech |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 9:33 | 1,530,000,000,000,000,000 | well-known for its neurological drug development programs, has firmly planted its flag as an oncology company at the 's annual meeting.
#alkermes #oncology #asco22 #biospace | Your source for biopharma news and jobs | Company / Organization | Media / News |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 9:59 | 1,530,000,000,000,000,000 | well-known for its neurological drug development programs, has firmly planted its flag as an oncology company at the 's annual meeting.
#alkermes #oncology #asco22 #biospace | Marcus & Associates is a leading life sciences executive search firm helping clients identify and acquire the industry's'? most talented individuals. | Company / Organization | Consulting / Analytics |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 11:57 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at asco 22 | BioCalifornia is committed to the growth of life sciences, and commercialization of discoveries to improve human health, the environment, and sustainability. | Company / Organization | Healthcare |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 12:31 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at asco 22 | Everything pharma. | Bot / Aggregator | Media / News |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 12:31 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at asco 22 | All things biotech. | Bot / Aggregator | Media / News |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/6/2022 12:31 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at asco 22 | null | Bot / Aggregator | Media / News |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/7/2022 11:23 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at #asco 22 | biospace #jobs | Man of faith, Sr. Writer for @biospace, Lead Writer for @biobuzzmaryland Writer for #OnwardBoundRPG, https://t.co/OWBwxJNa57 Author: Pains of the Past https://t.co/zfUGiDoHEO | Individual | Media / News |
not tagged | not tagged | alkermes | not tagged | 1 | ['alkermes'] | 6/7/2022 6:10 | 1,530,000,000,000,000,000 | alkermes plants oncology flag at asco 22 - biospace #plants | Twitter Home for LawnShapes DBA | Bot / Aggregator | Media / News |
ARTISTRY-7 | Nemvaleukin,pembrolizumab | alkermes,merck | other | 1 | ['ovarian'] | 6/5/2022 13:00 | 1,530,000,000,000,000,000 | a new #clinicaltrial, artistry-7, studying the effectiveness of a combination of #immunotherapy treatments could be more effective for patients with #ovariancancer who are resistant to traditional interventions: #asco22 #oncnews | Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology | Company / Organization | Publication / Journal |
artistry-7 | pembrolizumab,nemvaleukin | alkermes,merck | other | 1 | ['ovarian', 'artistry-7', 'alkermes'] | 6/7/2022 7:48 | 1,530,000,000,000,000,000 | a large unmet need remains for more treatment options for patients living with platinum-resistant ovarian cancer. this need drives the ongoing research in our artistry-7 clinical trial. learn more about our work at #asco22. | Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc | Company / Organization | Pharma / Biotech |
not tagged | aglatimagene besadenovec,act-903 | alpha cancer technologies,candel therapeutics | thoracic | 1 | ['sclc', 'can-2409', 'act 903', 'nsclc'] | 6/6/2022 11:13 | 1,530,000,000,000,000,000 | the new frontier: oncolytic viral immunotherapy. a lot of interest at #asco2022 in #candeltherapeutics abstract 9037, showing initial results for #can-2409 in #nsclc. | Physician-scientist. Immunologist. CEO of Candel Therapeutics ($CADL), focused on development of new immunotherapies for cancer. Views expressed here are my own | Individual | HCP |
Not Tagged | erfonrilimab | alphamab | Not Tagged | 1 | ['kn046'] | 6/5/2022 20:53 | 1,530,000,000,000,000,000 | research updates on kn046 presented at 2022 asco | null | Bot / Aggregator | Finance / Investment |
Not Tagged | anbenitamab | alphamab | Not Tagged | 1 | ['kn026'] | 6/5/2022 22:01 | 1,530,000,000,000,000,000 | poster highlighting phase ii clinical study of kn026 for her2-expressing advanced gc/gej presented at 2022 asco | null | Bot / Aggregator | Finance / Investment |
Not Tagged | anbenitamab | alphamab | Not Tagged | 1 | ['kn026'] | 6/5/2022 23:33 | 1,530,000,000,000,000,000 | poster highlighting phase ii clinical study of kn026 for her2-expressing advanced gc/gej presented at 2022 asco | The Headlines of Today is a World News Website, Provide World News, International Breaking News, Tech , spots and entertainment News | Bot / Aggregator | Media / News |
neon-1 | alpn-202 | alpine immune sciences | lymphoma | 1 | ['neon-1'] | 6/7/2022 12:10 | 1,530,000,000,000,000,000 | , mbbs, msc from spoke with us about #asco22 - dose escalation - neon-1 study, a conditional cd2 8 costimulator and dual point inhibitor. #oncotwitter | Produce, Find, and Distribute the latest and highest quality multimedia to oncologists, hematologists and researchers. | Bot / Aggregator | Media / News |
neon-1 | alpn-202 | alpine immune sciences | lymphoma | 1 | ['neon-1'] | 6/7/2022 12:10 | 1,530,000,000,000,000,000 | , mbbs, msc from spoke with us about #asco22 - dose escalation - neon-1 study, a conditional cd2 8 costimulator and dual point inhibitor. #oncotwitter | Produce, Find, and Distribute the latest and highest quality multimedia to oncologists, hematologists and researchers. | Bot / Aggregator | Media / News |
Not Tagged | leronlimab | amfar,cytodyn,vyera pharmaceuticals | Not Tagged | 1 | ['leronlimab'] | 6/5/2022 0:39 | 1,530,000,000,000,000,000 | #leronlimab saves lives here it is , take a look judge for yourself ... enjoy .program guide asco meeting program guide | Life of Pi | Individual | Blogger / Random / Other |
Not Tagged | leronlimab | amfar,cytodyn,vyera pharmaceuticals | Not Tagged | 1 | ['leronlimab'] | 6/5/2022 0:40 | 1,530,000,000,000,000,000 | #leronlimab saving lives program guide asco meeting program guide | Life of Pi | Individual | Blogger / Random / Other |
Not Tagged | leronlimab | amfar,cytodyn,vyera pharmaceuticals | other | 1 | ['tnbc', 'leronlimab', 'cytodyn'] | 6/5/2022 3:52 | 1,530,000,000,000,000,000 | #leronlimab for #mtnbc safety, efficacy, and clinical outcomes of the anti-ccr5 inhibitor (leronlimab): a pooled analysis of three clinical trials in patients with mtnbc. #cytodyn #ccr5 | ?? ???? ????? ????? ??????? ???????? ???? ?????? ????????? ??? ???? ?????????? ????? ????? ??????? | Individual | Blogger / Random / Other |
not tagged | leronlimab | amfar,vyera pharmaceuticals,cytodyn | not tagged | 1 | ['leronlimab'] | 6/7/2022 1:13 | 1,530,000,000,000,000,000 | #leronlimab #cancer perhaps one of these co. s will be a future partner i believe i know | null | Bot / Aggregator | Blogger / Random / Other |
Not Tagged | sotorasib | amgen | gi,thoracic | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nsclc', 'sotorasib', 'sclc'] | 6/4/2022 8:51 | 1,530,000,000,000,000,000 | mechanisms of acquired resistance by ctdna to sotorasib (kras g12c inh) for nsclc & crc: rtk mutations are the majority but alterations are heterogeneous! potential for combination therapies ! work by dr bob li #asco22 | Director, @danaFarber_GU & International Strategic Initiatives @DanaFarber. Kohlberg Prof. of Medicine @Harvardmed. @PanMass rider. #SoccerIsLife. Views Mine. | Individual | HCP |
Not Tagged | sotorasib | amgen | gi,thoracic | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'lcsm,(-blcsm)', 'nsclc', 'sotorasib', 'biomarker', 'sclc'] | 6/4/2022 10:10 | 1,530,000,000,000,000,000 | acquired resistance to sotorasib in kras g12c mutant nsclc (n=67) and crc (n=45) utilizing plasma biomarker--> acquired alterations involving multiple signaling pathways w/ rtk gene alterations being the most prevalent #lcsm #asco22 | Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own | Individual | HCP |
codebreak 100 | sotorasib | amgen | gi,thoracic | 1 | ['sotorasib'] | 6/4/2022 8:43 | 1,530,000,000,000,000,000 | #precisionmedicine at #asco22 during the fantastic liquid biopsy session chaired by - now up ctdna analyses within codebreak investigating markers of resistance to sotorasib. #precisiononcology | Physician-scientist passionate about #PrecisionOncology ?? & #PancreaticCancer ?? •@myesmo faculty •Rolling with @OncoAlert?? •Views are my own• | Individual | HCP |
codebreak 100 | sotorasib | amgen | gi,thoracic | 1 | ['codebreak 100'] | 6/4/2022 8:44 | 1,530,000,000,000,000,000 | codebreak 100: presentation from bob li. acquired resistance using ctdna from paired samples at baseline and pd. v high rate of dna shedding. 28% have a new aq resistance genomic alteration. multiple and diverse pathways #asco2022 | Consultant Medical Oncologist, UK. Views are hypothesis generating discourse. Post COVID dabbling in garden. | Individual | HCP |
codebreak 100 | sotorasib | amgen | gi,thoracic | 1 | ['nsclc', 'codebreak100', 'sotorasib', 'sclc'] | 6/4/2022 8:47 | 1,530,000,000,000,000,000 | dr li reports sotorasib resistance mechanisms by 23gene resolution bioscience hybridization capture ctdna from codebreak100 nsclc.93% shed ctdna baseline. 28% had acquired genotypes. heterogenous variants. ?differences in mutations by pfs slow vs fast #asco22 | Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own. Wear a mask, keep distant, get the vaccine & then a booster! | Individual | HCP |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'lcsm,(-blcsm)', 'nsclc', 'codebreak100', 'lung', 'sotorasib', 'biomarker', 'sclc'] | 6/4/2022 8:54 | 1,530,000,000,000,000,000 | acquired resistance to sotorasib by plasma biomarker analysis in codebreak100 (lung and crc). elegant presentation at #asco22 #ctdna session.
the occurrence of multiple mutations characterises fast progressors among #nsclc patients. #lcsm | Medical Oncologist | Research Fellow @GustaveRoussy | Ph.D. Student @UniGenova | Clinical and #TranslationalResearch | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['pancsm', 'sequence,(-consequence)', 'pancreatic'] | 6/5/2022 10:23 | 1,530,000,000,000,000,000 | so these are surprisingly good results for the sequence trial in #pancreaticcancer presented at #asco22 - i wonder what my #pancsm colleagues say: ? #pancsm | Physician-scientist passionate about #PrecisionOncology ?? & #PancreaticCancer ?? •@myesmo faculty •Rolling with @OncoAlert?? •Views are my own• | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['pancsm', 'sequence,(-consequence)', 'pancreatic'] | 6/5/2022 10:17 | 1,530,000,000,000,000,000 | important question in #pancreaticcancer is there a benefit due to sequential treatment? we are about to get some data at #asco22 from the sequence trial. #pancsm ps: i spotted my great colleague on the rational slide | Physician-scientist passionate about #PrecisionOncology ?? & #PancreaticCancer ?? •@myesmo faculty •Rolling with @OncoAlert?? •Views are my own• | Individual | HCP |
codebreak 100 | sotorasib | amgen | thoracic,gi | 1 | ['sotorasib', 'codebreak100'] | 6/5/2022 17:07 | 1,530,000,000,000,000,000 | #asco22
sotorasib
#krasg12c codebreak100 subsets story of #precisionmedicine. while we still have to have a larger impact for those with all patients with pancreas cancer, for the ones with #krasg12c, options opening up in the undruggable kras. combinations next. | Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22 | Individual | HCP |
codebreak 100 | sotorasib | amgen | thoracic,gi | 1 | ['nsclc', 'lung', 'lcsm,(-blcsm)', 'sotorasib', 'sclc', 'codebreak100'] | 6/5/2022 0:04 | 1,530,000,000,000,000,000 | #asco22 day 2: #lungcancer educational highlights 4/4 resistance to #sotorasib in #krasg12c nsclc: ctdna analysis #codebreak100.
by dr. bob t li acquired resistance in 28% rtk most common-targetable #lcsm #medtwitter | Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her) | Individual | HCP |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:20 | 1,530,000,000,000,000,000 | a new map for maintenance? atlas: krd (response adapted) vs r maint post asct. pfs 59 m vs 41 m. tox comparable. mrd-adapted results still favor krd. as usual more drugs=better but maybe a pathway to limit duration of tx for some? #mmsm #asco2022 | null | Individual | HCP |
Not Tagged | talimogene | amgen | melanoma | 1 | ['talimogene laherparepvec', 'melanoma'] | 6/5/2022 8:45 | 1,530,000,000,000,000,000 | at the #asco22 oral abstract session on #melanoma? read about the phase ii trial on neoadjuvant talimogene laherparepvec plus surgery versus surgery alone, led by speaker reinhard dummer | Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians. | Company / Organization | Publication / Journal |
sequence | abraxane,paclitaxel | amgen | other | 1 | ['sequence,(-consequence)'] | 6/5/2022 10:27 | 1,530,000,000,000,000,000 | can we sequence when we have a limited toolbox?? gem/nab-p followed by folfox for the win?? hard sell? #asco22 | GI Oncologist, focus pancreatic, biliary cancers, personalized tx’s. Love to dance, travel, and spend time with my family. ASCO FCOI: https://t.co/oXHqwABv0w | Individual | HCP |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 12:20 | 1,530,000,000,000,000,000 | #asco22: phase 3 atlas study results show that maintenance w/ extended krd after induction treatment following asct improves pfs compared to standard lenalidomide maintenance in pts w/ newly diagnosed mm. #ascodailynews #hemonc #mmsm | Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse. | Company / Organization | Professional |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'nsclc', 'codebreak100', 'lung', 'sotorasib', 'rectal', 'biomarker', 'sclc', 'colorectal'] | 6/4/2022 8:40 | 1,530,000,000,000,000,000 | largest evaluation of acquired resistance to sotorasib in kras p.g12c-mutated non small cell lung cancer (nsclc) and colorectal cancer (crc): plasma biomarker analysis of codebreak100. talk by dr. bob t li #crcsm #asco22 | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
sequence | abraxane,paclitaxel | amgen | gi,other,other | 1 | ['sequence,(-consequence)', '4022', 'pancreatic', 'gi '] | 6/5/2022 4:00 | 1,530,000,000,000,000,000 | ttd highligts check the pancreatic cancer track at #asco22 meeting. don't miss it! ttd oral abstract session- 4022 the sequence trial sunday, june 5, 17:12 cest : #ttdupdates #uppergi | TTD Group-Grupo Español de Tratamiento de los Tumores Digestivos. Fomentamos la investigación clínica, traslacional y epidemiológica de los cánceres digestivos | Company / Organization | Hospital / Clinic |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:18 | 1,530,000,000,000,000,000 | the atlas trial presented at #asco22
-given design (3 drugs maint, and pfs as endpoint), answer was obvious.
-low power to detect any survival difference
-no quality of life presented, suspect would be worse if properly measured in krd arm
-please don t adopt in practice! #mmsm | Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own. | Individual | HCP |
Not Tagged | patritumab | amgen,daiichi sankyo | thoracic | 1 | ['lung'] | 6/6/2022 13:45 | 1,530,000,000,000,000,000 | mentions the initial paper on patritumumab deruxtecan (her3-dxd) in her #asco22 lung cancer poster discussion | Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Tweets are my own. She/her | Individual | Publication / Journal |
codebreak 100 | sotorasib | amgen | thoracic,gi,other | 1 | ['codebreak100', 'pancreatic', 'sotorasib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm'] | 6/6/2022 14:30 | 1,530,000,000,000,000,000 | codebreak100: sotorasib in heavily pretreated met pancreatic ca with kras p.g12c mut > orr 21% and dcr 84%. further randomized trials needed and are ongoing! #asco22 #crcsm #asco2022 | ???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement” | Individual | HCP |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['thanks', 'amgen'] | 6/5/2022 12:50 | 1,530,000,000,000,000,000 | thanks dianna mulzac for visiting my poster & sharing photo i took on her phone of dr. katie runcie on cab ride (from hell; not the passengers who had nice conversations headed to different destinations) #asco22 | Physician-Scientist; Translational Oncologist https://t.co/8RMRruPhfx Director @BrownUCancer Associate Dean @BrownMedicine | Individual | HCP |
Not Tagged | Not Tagged | amgen | other,thoracic | 1 | ['lung', 'sclc', 'nsclc', 'biomarker', 'amgen', 'amgenoncology'] | 6/3/2022 12:00 | 1,530,000,000,000,000,000 | while biomarker testing is revolutionizing the treatment of lung cancer for some patients, many people diagnosed with #nsclc (non-small cell lung cancer) don t know their biomarker status. take the i test for kras g12c pledge today to help get the word out! #asco22 | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | amgen | thoracic,other | 1 | ['biomarker', 'nsclc', 'lung', 'sclc', 'amgenoncology', 'amgen'] | 6/5/2022 8:00 | 1,530,000,000,000,000,000 | lung cancer biomarker testing can potentially lead to more information on treatment options. 1 in 8 people living with non-small cell lung cancer (#nsclc) have the kras g12c biomarker. that s why it s essential to share testing information & expand access. #asco22 | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:30 | 1,530,000,000,000,000,000 | myeloma time! atlas trial compares krd maintenance with len maintenance. as dr voorhees asks: at what point to side effects. treatment fatigue and cost outweigh improvements in pfs? (and why is pfs the primary endpoint of a maintenance trial?) #mmsm #asco22 #atlas | haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder | Individual | Research / Science |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:44 | 1,530,000,000,000,000,000 | congress #asco22 | dominik dytfeld presents the atlas trial, which asses the efficacy and safety of mrd-guided krd maintenance after auto-hsct #mmsm | The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma | Company / Organization | Healthcare |
sequence | abraxane,paclitaxel | amgen | other | 1 | ['sequence,(-consequence)'] | 6/5/2022 10:41 | 1,530,000,000,000,000,000 | last - what if we "sequenced" q2week gem-nab-pac with folfox better tolerated, and equally effective? btw - awesome job (what else!) by on the discussion | GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['sequence,(-consequence)', 'pancreatic'] | 6/5/2022 10:42 | 1,530,000,000,000,000,000 | and now the inimitable places conko in context plus helps us decide on sequence in #pancreaticcancer #asco22 | GI Oncologist, focus pancreatic, biliary cancers, personalized tx’s. Love to dance, travel, and spend time with my family. ASCO FCOI: https://t.co/oXHqwABv0w | Individual | HCP |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 19:27 | 1,530,000,000,000,000,000 | just by reviewing the atlas trial and assuming i will offer another drug to myeloma patients beside lenalidomide! why is it better than dara (sc) or velcade (sc) !! no os benefit #mmsm #asco22 | Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter | Individual | HCP |
not tagged | not tagged | amgen | other,thoracic | 1 | ['sclc', 'lung', 'biomarker', 'nsclc', 'amgenoncology', 'amgen'] | 6/6/2022 11:09 | 1,530,000,000,000,000,000 | during #asco22, conference attendees can try out our new kras g12c challenge at the booth 18041. in this virtual game, healthcare providers get to experience what it s like to perform biopsies & test for biomarkers in non-small cell lung cancer (#nsclc). see it in action! | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['amgen', 'amgenoncology'] | 6/3/2022 10:00 | 1,530,000,000,000,000,000 | we re excited to be back in chicago for #asco22! you can learn about s innovative portfolio & pipeline at our booth 18041. | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['friends', 'amgen'] | 6/3/2022 16:56 | 1,530,000,000,000,000,000 | great conversations at #asco22 with our friends at ! | We FIGHT to cure #colorectalcancer and serve as #RelentlessChampions of hope for all affected by this disease! ???? | Company / Organization | Advocacy / Charity |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['nsclc', 'codebreak100', 'sotorasib', 'rectal', 'biomarker', 'sclc', 'colorectal'] | 6/4/2022 8:44 | 1,530,000,000,000,000,000 | msk's dr. bob li presents at #asco22 on "largest evaluation of acquired resistance to #sotorasib in #kras p.g12c-mutated #nsclc and colorectal cancer: plasma biomarker analysis of codebreak100." | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'nsclc', 'codebreak100', 'biomarker', 'sclc'] | 6/4/2022 8:44 | 1,530,000,000,000,000,000 | plasma biomarker analysis of codebreak100. talk by dr. bob t li #crcsm #asco22 guardant360 for #crc cohort
1st nsclc- 63% did not have acquired alterations at progression 10 of 31 mutations were actionable | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'nsclc', 'codebreak100', 'biomarker', 'sclc'] | 6/4/2022 8:47 | 1,530,000,000,000,000,000 | plasma biomarker analysis of codebreak100. talk by dr. bob t li #crcsm #asco22
1st nsclc:
2nd crc: 75% of pts had acquired mutations at progression, 16/100 new mutations were actionable | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
codebreak 100 | sotorasib | amgen | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'codebreak100', 'biomarker'] | 6/4/2022 8:51 | 1,530,000,000,000,000,000 | plasma biomarker analysis of codebreak100. talk by dr. bob t li #crcsm #asco22 | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['amgen'] | 6/4/2022 10:28 | 1,530,000,000,000,000,000 | streaming from chicago, il #asco22 | Founder of the Chris Draft Family Foundation, Co-Founder @Teamdraft with #KRD #WeAreGoingtoFight . NFL Ambassador @NFLPlayerEngage. Motivational speaker. | Company / Organization | Advocacy / Charity |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:31 | 1,530,000,000,000,000,000 | in abstract discussion, great slide summarizing financial toxicity (and time toxicity!) of krd maintenance in atlas versus r maintenance. pros must be included and considered. #mmsm #asco22 | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other | 1 | ['sequence,(-consequence)'] | 6/5/2022 10:21 | 1,530,000,000,000,000,000 | dr. carrato presents the sequence trial, gem/nab-p followed by folfox vs gem/nab-p for pdac. pfs 7.9 vs 5.2 months (hr 0.51) and os 13.2 vs 9.7 months (hr 0.676). 12m os rate (primary endpoint) 55.3 vs 35.4%. #asco22 | Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine. | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['sequence,(-consequence)', 'pancreatic'] | 6/5/2022 11:14 | 1,530,000,000,000,000,000 | #asco2022 sequential nab-paclitaxel/gemcitabine followed by modified folfox increase survival compared to standatd nab/gem for first-line metastatic pancreatic cancer : sequence trial by and spanish collaborators | null | Individual | Research / Science |
ConCERT | panitumumab | Amgen | Not Tagged | 1 | ['radio'] | 6/5/2022 11:15 | 1,530,000,000,000,000,000 | an open-label, noninferiority phase iii rct of weekly versus three weekly cisplatin and radical radiotherapy in lahnscc (concert trial) | #asco22
complement to jcog1008 in the definitive setting | @KP_LAMC Radiation Oncology Residency APD ?? | @KPMedSchool Assistant Professor and Radiation Oncology Clerkship Director | @UCBerkeley GO BEARS! ?? | Individual | HCP |
not tagged | not tagged | amgen | not tagged | 1 | ['amgenoncology', 'amgen'] | 6/6/2022 14:23 | 1,530,000,000,000,000,000 | it s been too long, chicago! we re thrilled to return to the windy city, where we ve been meeting with members of the global oncology community at #asco22. tune in for the top 5 reasons our team members are glad to be back | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
codebreak 100 | sotorasib | amgen | gi,thoracic | 1 | ['lcsm,(-blcsm)', 'nsclc', 'codebreak100', 'sotorasib', 'sclc'] | 6/4/2022 8:57 | 1,530,000,000,000,000,000 | study on mech of resistnce to sotorasib, lookd @ acquired alterations in ctdna in nsclc kras g12c pts (codebreak100). reslts suggst many paths of resistnce may occur @ progresn particu in rtk path. groundwork for combo tx studies #asco22 #lcsm #kras #nsclc | LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer. | Company / Organization | Advocacy / Charity |
Not Tagged | Not Tagged | amgen | gi | 1 | ['esophageal', 'gastric', 'gastroesophageal', 'amgenoncology', 'amgen'] | 6/4/2022 8:59 | 1,530,000,000,000,000,000 | learn more about #fgfr2b, an emerging target for new potential therapies for a variety of malignancies, including gastric or gastroesophageal junction cancer. #asco22 | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |